You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

sintilimab

Showing 26 - 50 of 163
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Wuhan (HAIC, Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Nov 8, 2022

NSCLC (Non-small-cell Lung Cancer) Trial in Changchun (Sintilimab, IBI310)

Recruiting
  • NSCLC (Non-small-cell Lung Cancer)
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Sep 21, 2022

Gastric Adenocarcinoma Trial in Guangzhou (Sintilimab, Ramucirumab, Cisplatin)

Active, not recruiting
  • Gastric Adenocarcinoma
  • Sintilimab
  • +5 more
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Gastric Cancer Trial (Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Sintilimab
  • (no location specified)
Oct 21, 2022

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Sintilimab)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Sintilimab
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 8, 2022

Hepatocellular Carcinoma Trial in Shanghai (IBI310, Sintilimab, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, Shanghai, China
    Fudan Universtiy Zhongshan Hospital
Sep 16, 2022

Cancer of Unknown Primary Site Trial in Houston (Sintilimab)

Recruiting
  • Cancer of Unknown Primary Site
  • Sintilimab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 31, 2022

Pancreatic Tumors Trial in Guangzhou (Surufatinib, Sintilimab, AG)

Not yet recruiting
  • Pancreatic Neoplasms
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Jul 28, 2022

Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)

Recruiting
  • Classic Hodgkin's Lymphoma
  • Sintilimab
  • +4 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022

NSCLC Trial in Hangzhou (sintilimab, pemetrexed, Carboplatin)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • sintilimab
  • +3 more
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Jul 11, 2022

Rectal Cancer Trial in Guangzhou (Sintilimab)

Recruiting
  • Rectal Cancer
  • Sintilimab
  • Guangzhou, Guangdong, China
    Department of colorectal surgery, the Sixth Affiliated Hospital,
Jul 11, 2022

Esophageal Squamous Cell Carcinoma Trial in Nanjing (Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Sintilimab
  • Liposomal Paclitaxel + Cisplatin + S-1
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Jul 16, 2022

Breast Cancer Trial in Shanghai (sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin)

Recruiting
  • Breast Cancer
  • sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 22, 2022

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Sintilimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

SCLC Trial in Shanghai (Carboplatin, Cisplatin, Etoposide)

Active, not recruiting
  • SCLC
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jul 18, 2022

Advanced NSCLC Trial in Jilin (pemetrexed, Cetuximab, cis-platinum)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Jilin, Changchun, China
    Jilin Province Cancer Hospital
Aug 15, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Squamous Cell NSCLC Trial in Hangzhou (Sintilimab, Carboplatin, Albumin-Bound Paclitaxel)

Not yet recruiting
  • Squamous Cell Non-small Cell Lung Cancer
  • Sintilimab
  • +2 more
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Jun 19, 2022

Nasopharyngeal Tumors Trial in China (Sintilimab, Gemcitabine, Cisplatin)

Active, not recruiting
  • Nasopharyngeal Neoplasms
  • Sintilimab
  • +3 more
  • Foshan, Guangdong, China
  • +8 more
Oct 6, 2022

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Sintilimab
  • +5 more
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

Recruiting
  • Advanced Non-squamous Non-Small-Cell Lung Cancer
  • Sintilimab
  • Jinan, Shandong, China
    The First Affiliated Hospital of Shandong First Medical Universi
Dec 4, 2022

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Sintilimab
  • +2 more
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • EGFR Activating Mutation
  • Sintilimab
  • +2 more
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Aug 8, 2022

Colorectal Tumors Trial in Xiamen (hypofractionation Radiotherapy, sintilimab, GM-CSF)

Recruiting
  • Colorectal Neoplasms
  • hypofractionation Radiotherapy
  • +3 more
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Mar 28, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Sintilimab, Capecitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 5, 2022